NEJ009 is the first phase III study to evaluate the efficacy of a combination of EGFR-TKI plus platinum combination therapy, used in conjunction with standard EGFR-TKI monotherapy for the treatment of advanced non-small-cell lung cancer harboring EGFR mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.